---
title: "Viatris Inc. Stock Rises Tuesday, Outperforms Market"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275518145.md"
description: "Shares of Viatris Inc. (VTRS) rose 2.51% to $15.95 on Tuesday, outperforming the market amid mixed trading conditions. This marks the stock's third consecutive day of gains and a new 52-week high, surpassing its previous peak of $15.60. Trading volume reached 17.4 million, exceeding the 50-day average of 8.7 million."
datetime: "2026-02-10T22:10:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275518145.md)
  - [en](https://longbridge.com/en/news/275518145.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275518145.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275518145.md) | [English](https://longbridge.com/en/news/275518145.md)


# Viatris Inc. Stock Rises Tuesday, Outperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Viatris Inc. (VTRS) rose 2.51% to $15.95 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.10% to 50,188.14 and the S&P 500 Index falling 0.33% to 6,941.81.

This was the stock's third consecutive day of gains.

Viatris Inc. hit a new 52-week high, surpassing its previous peak of $15.60, which the company reached on February 9th.

Trading volume (17.4 M) eclipsed its 50-day average volume of 8.7 M.

Data source: Dow Jones Market Data, FactSet. Data compiled February 10, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

02-10-26 1710ET

### 相關股票

- [Viatris (VTRS.US)](https://longbridge.com/zh-HK/quote/VTRS.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)

## 相關資訊與研究

- [Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research](https://longbridge.com/zh-HK/news/278908205.md)
- [A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review](https://longbridge.com/zh-HK/news/277640565.md)
- [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/zh-HK/news/278448836.md)
- [Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data](https://longbridge.com/zh-HK/news/278566951.md)
- [Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market](https://longbridge.com/zh-HK/news/278917368.md)